By targeting these promoters, HOXDeRNA evicts the Polycomb repressive complex 2 (PRC2), specifically displacing EZH2, thereby releasing key glioma driver genes from epigenetic silencing. This evidence concerns the gene EZH2 and central nervous system cancer.